3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
12
Lung Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Oropharyngeal Neoplasms
10
Glioblastoma
10
Breast Neoplasms
9
Urinary Bladder Neoplasms
7
Glioma
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Neoplasm Metastasis
5
Mouth Neoplasms
5
Esophageal Neoplasms
5
Carcinoma
5
Burkitt Lymphoma
5
Astrocytoma
5
Uterine Cervical Neoplasms
4
Rhabdomyosarcoma
4
Pancreatic Neoplasms
4
Laryngeal Neoplasms
4
Histiocytoma, Malignant Fibrous
4
Gliosarcoma
4
Carcinoma, Hepatocellular
4
Adenocarcinoma of Lung
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Sarcoma, Synovial
3
Rhabdomyosarcoma, Embryonal
3
Rectal Neoplasms
3
Neoplasms
3
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Radiation
×
90 days
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled